Ask AI
Atopic Dermatitis and IL-4/IL-13 and IL-13 Targeted Therapies
Interactive Case Challenges: Atopic Dermatitis and IL-4/IL-13 and IL-13 Targeted Therapies

Released: April 30, 2025

Activity

Progress
1
Course Completed

Case History and Presentation
During his follow-up visit while still receiving tralokinumab 300 mg every 2 weeks, Jeremy feels optimistic about his progress and asks his dermatologist about the next steps for long-term management. Specifically, he inquires about the duration of tralokinumab therapy, potential risks of prolonged use, and whether additional lifestyle modifications or treatments are recommended to maintain his current level of control. He is eager to sustain these improvements and minimize the likelihood of flare-ups in the future. Jeremy’s dermatologist discusses the importance of ongoing therapy and regular follow-ups to ensure continued symptom control and prevent relapses.

What is the most appropriate recommendation for Jeremy’s long-term management of AD?